<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04097938</url>
  </required_header>
  <id_info>
    <org_study_id>GLPG3667-CL-101</org_study_id>
    <secondary_id>2019-001659-38</secondary_id>
    <nct_id>NCT04097938</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effects of Single and Multiple Oral Doses of GLPG3667</brief_title>
  <official_title>A First-in-human Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of GLPG3667 in Adult, Healthy, Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galapagos NV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galapagos NV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a first-in-human, Phase I, randomized, double-blind, placebo-controlled,
      single-center, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics
      (PK) and pharmacodynamics of GLPG3667 after oral single ascending doses (SAD) of GLPG3667
      (part 1) and after oral multiple ascending doses (MAD) for 13 days of GLPG3667 (part 2) in
      healthy male subjects. In addition, the effect of food (FE) on safety, tolerability, and PK
      of GLPG3667 oral suspension will be evaluated (part 3 - will not be completed), and the
      relative bioavailability (rBA) of the capsule versus the oral suspension with the effect of
      food on the bioavailability of the capsule (part 4), both part 3 and 4 using an open-label,
      randomized, crossover design.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 18, 2019</start_date>
  <completion_date type="Actual">July 6, 2020</completion_date>
  <primary_completion_date type="Actual">March 4, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency and severity of treatment-emergent adverse events (TEAEs), treatment-emergent serious adverse events, and TEAEs leading to treatment discontinuations</measure>
    <time_frame>From screening through study completion, an average of 5 months</time_frame>
    <description>To evaluate the safety and tolerability of single and multiple ascending oral doses of GLPG3667, in adult, healthy, male subjects compared with placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of GLPG3667 (μg/mL)</measure>
    <time_frame>Between Day 1 pre-dose and Day 16</time_frame>
    <description>To evaluate the pharmacokinetics (PK) of single and multiple ascending oral doses of GLPG3667, in adult, healthy, male subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under curve (AUC) of GLPG3667 (μg.h/mL)</measure>
    <time_frame>Between Day 1 pre-dose and Day 16</time_frame>
    <description>To evaluate the PK of single and multiple ascending oral doses of GLPG3667, in adult, healthy, male subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination half-life (t1/2) of GLPG3667 (h)</measure>
    <time_frame>Between Day 1 pre-dose and Day 16</time_frame>
    <description>To evaluate the PK of single and multiple ascending oral doses of GLPG3667, in adult, healthy, male subjects</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>GLPG3667 SAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single doses of GLPG3667 at up to 6 dose levels in ascending order</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo SAD</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single doses of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLPG3667 MAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple doses of GLPG3667 at up to 3 dose levels in ascending order, daily for 13 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo MAD</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple doses of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLPG3667 FE fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of GLPG3667 in fasted state</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLPG3667 FE fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of GLPG3667 in fed state</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLPG3667 oral suspension rBA-FE fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of GLPG3667 oral suspension in fed state</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLPG3667 capsules rBA-FE fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of GLPG3667 capsules in fasted state</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLPG3667 capsules rBA-FE fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of GLPG3667 capsules in fed state</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLPG3667 oral suspension</intervention_name>
    <description>GLPG3667 oral suspension</description>
    <arm_group_label>GLPG3667 FE fasted</arm_group_label>
    <arm_group_label>GLPG3667 FE fed</arm_group_label>
    <arm_group_label>GLPG3667 MAD</arm_group_label>
    <arm_group_label>GLPG3667 SAD</arm_group_label>
    <arm_group_label>GLPG3667 oral suspension rBA-FE fed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Placebo oral suspension</description>
    <arm_group_label>Placebo MAD</arm_group_label>
    <arm_group_label>Placebo SAD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLPG3667 capsules</intervention_name>
    <description>GLPG3667 capsules</description>
    <arm_group_label>GLPG3667 capsules rBA-FE fasted</arm_group_label>
    <arm_group_label>GLPG3667 capsules rBA-FE fed</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male between 18-55 years of age (extremes included), on the date of signing the
             informed consent form (ICF)

          -  A body mass index (BMI) between 18-30 kg/m2, inclusive

          -  Judged to be in good health by the investigator based upon the results of a medical
             history, physical examination, vital signs, 12-lead electrocardiogram (ECG), and
             fasting clinical laboratory safety tests, available at screening and prior to
             randomization. Hemoglobin, neutrophil, lymphocyte, and platelet counts must be above
             the lower limit of normal range. Bilirubin, aspartate aminotransferase (AST), and
             alanine aminotransferase (ALT) must be within normal ranges. Other clinical laboratory
             safety test results must be within the reference ranges or test results that are
             outside the reference ranges need to be considered not clinically significant in the
             opinion of the investigator

        Exclusion Criteria:

          -  Known hypersensitivity to Investigational Medicinal Product (IMP) ingredients or
             history of a significant allergic reaction to IMP ingredients as determined by the
             investigator

          -  Known contraindication or hypersensitivity to Interferon-alpha (IFN-α) or any
             component of Intron-A® (Note: this criterion is only applicable to subjects in the MAD
             part)

          -  Positive serology for hepatitis B virus surface antigen (HBsAg) or hepatitis C virus
             (HCV) or history of hepatitis from any cause with the exception of hepatitis A that
             was resolved at least 3 months prior to first dosing of the IMP.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Magdalena Petkova, MD</last_name>
    <role>Study Director</role>
    <affiliation>Galapagos NV</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SGS Belgium NV - Clinical Pharmacology Unit Antwerp</name>
      <address>
        <city>Antwerp</city>
        <zip>2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 19, 2019</study_first_submitted>
  <study_first_submitted_qc>September 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2019</study_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

